Sanofi (($SNYNF)) announced an update on their ongoing clinical study. Sanofi is conducting a study titled ‘A Phase 2b/3, Randomized, ...

The Chronic Obstructive Pulmonary Disease Pipeline report embraces in-depth commercial and clinical assessment of the ...

Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic ...

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...

On Wednesday, the FDA approved Verona Pharma plc’s (NASDAQ:VRNA) Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvayre is ...

Please provide your email address to receive an email when new articles are posted on . Remodeling may include more smooth muscle mass and epithelial cell shedding. Macrolides, vaccination and ...

Please provide your email address to receive an email when new articles are posted on . During a 5-year period, 45,079 of 156,462 patients with GOLD A/B COPD progressed to GOLD E. More patients moved ...

An inhalable drug treatment for chronic obstructive pulmonary disease received FDA-approval June 26, drugmaker Verona Pharma announced. It is the first FDA-approved treatment for COPD in more than two ...

COPD 5-year mortality was most likely in patients receiving long-term oxygen therapy, oral corticosteroids, and triple therapy. Increasing treatment intensity levels (TILs) in patients with chronic ...

Chronic obstructive pulmonary disease (COPD), a condition that affects more than 14 million U.S. adults, is marked by damage to the airways. It typically refers to emphysema and chronic bronchitis.